Form 4: Biogen CAO Sean Godbout Reports Stock Transactions

Biogen's Chief Accounting Officer, Sean Godbout, reported the acquisition of common stock through RSU vesting and a subsequent sale for tax withholding purposes.

Summary

• Sean Godbout, Chief Accounting Officer of Biogen Inc. (BIIB), reported transactions involving the company's common stock.
• On October 2, 2025, Mr. Godbout acquired 26 shares of common stock through the vesting of restricted stock units (RSUs).
• Concurrently, 8 shares were disposed of at a price of $155.25 per share to cover tax withholding obligations related to the RSU vesting.
• Following these transactions, Mr. Godbout directly beneficially owns 494.6667 shares of common stock.
• Additionally, 27 derivative securities (restricted stock units) remain beneficially owned.
• The vested 26 RSUs represent the second of three equal annual installments from a grant dated October 2, 2023. The final installment is scheduled to vest on October 2, 2026.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction (RSU vesting and tax-related sale) which is neutral in terms of company-specific sentiment. It reflects standard executive compensation practices.

Positives

• The vesting of 26 restricted stock units represents a scheduled compensation event for the Chief Accounting Officer, indicating adherence to executive incentive plans.

Negatives

• The sale of 8 shares of common stock at $155.25 per share was for tax withholding purposes, which is a routine and expected part of RSU vesting and not indicative of negative sentiment.

Future Outlook

The filing indicates a future RSU vesting event on October 2, 2026, for the remaining 27 restricted stock units.

Industry Context

This is a routine insider transaction filing (Form 4) and does not provide information relevant to broader industry trends or competitive landscape analysis.

Stakeholder Impact

• Shareholders: The transaction is a routine compensation event and does not directly impact the company's operational or financial performance. It represents a minor dilution from equity compensation.

Next Steps

• The final installment of 27 restricted stock units is scheduled to vest on October 2, 2026.

Key Dates

Recommendation

This Form 4 reports a routine insider transaction involving the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations. Such transactions are common for executives and do not typically indicate a change in the company's fundamental outlook or warrant a change in investment recommendation based solely on this filing. Investors should continue to evaluate Biogen based on its broader financial performance, pipeline, and market position.

Keywords

Biogen, BIIB, Form 4, Insider Transaction, Restricted Stock Unit, RSU Vesting, Sean Godbout, Chief Accounting Officer, Stock Transaction